Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (5191)
Born Freeport, NY
Graduated BUSM 1981
Residency - Graduate Hospital of the University of PA; '81-84
Fellowship -
PUPMC: '84-'86
AOH/Fox Chase: '86-'87
Staff: Fox Chase Cancer Center: '87-'08
Director of Thoracic Oncology and Professor of Medicine: University of Pennsylvania: since 2008
Editor: IASLC News
Published in
Speakers
Assistant Professor, Thoracic Oncology
Published in
Speakers
Dr. Victoria Lai is a clinical and translational investigator in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York, NY, USA. Her research focus is on small cell lung cancer and other pulmonary neuroendocrine diseases.
Published in
Speakers
David Kozono, MD, PhD, is a Senior Physician in Dana-Farber's Lowe Center for Thoracic Oncology and Assistant Professor of Radiation Oncology at Harvard Medical School. His clinical and research focus is on precision radiotherapy and multimodality therapy for lung cancer. He serves as the Co-Chair of the Immuno-Oncology Committee and Executive Officer for the Respiratory Committee of the Alliance for Clinical Trials in Oncology. In these roles he participates in the development and conduct of nationwide clinical trials testing novel targeted therapies and immunotherapy for lung cancer.
Published in
Speakers
Edward S. Kim, MD, MDA is senior vice president and physician-in-chief at City of Hope Orange County and vice physician-in-chief at City of Hope National Medical Center. Recently, Dr. Kim served as chairman of Solid Tumor Oncology and Investigational Therapeutics and medical director of clinical trials at Levine Cancer Institute, Atrium Health, Charlotte, NC. Prior, he was tenured associate professor in thoracic/head and neck medical oncology at University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Kim completed his MBA at University of North Carolina Keenan-Flagler School of Business.
Published in
Speakers
Dr. Fadlo R. Khuri is the 16th president of the American University of Beirut (AUB) and professor of medicine at the Faculty of Medicine and Medical Center.
Khuri is an accomplished molecular and translational oncologist, having authored over 750 publications. He serves as Editor in Chief of the journal Cancer. Prior to AUB, he was a professor and executive associate dean for research at Emory University School of Medicine and deputy director of the Winship Cancer Institute. Khuri was born in Boston and raised in Beirut. He earned his undergraduate degree at Yale University and MD at Columbia University College of Physicians and Surgeons.
Under Khuri’s leadership, AUB has reintroduced academic tenure and initiated several new PhD programs. He has helped obtain grants and donations for underprivileged students and patients totaling more than $250 million. In 2018, he spearheaded the effort to declare AUB a fully tobacco-free campus.
Khuri is leading the $650 million BOLDLY AUB capital campaign, which brought in the largest single gift in the university’s history. He also developed a new campus master plan and strategic plan: VITAL 2030. Khuri is a fellow of the American College of Physicians and his work has been recognized with several major awards.
Khuri is an accomplished molecular and translational oncologist, having authored over 750 publications. He serves as Editor in Chief of the journal Cancer. Prior to AUB, he was a professor and executive associate dean for research at Emory University School of Medicine and deputy director of the Winship Cancer Institute. Khuri was born in Boston and raised in Beirut. He earned his undergraduate degree at Yale University and MD at Columbia University College of Physicians and Surgeons.
Under Khuri’s leadership, AUB has reintroduced academic tenure and initiated several new PhD programs. He has helped obtain grants and donations for underprivileged students and patients totaling more than $250 million. In 2018, he spearheaded the effort to declare AUB a fully tobacco-free campus.
Khuri is leading the $650 million BOLDLY AUB capital campaign, which brought in the largest single gift in the university’s history. He also developed a new campus master plan and strategic plan: VITAL 2030. Khuri is a fellow of the American College of Physicians and his work has been recognized with several major awards.
Published in
Speakers
Karen Kelly, MD, FASCO is the Associate Director of Clinical Research at UC Davis and the Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research. Dr. Kelly received her medical degree from the University of Kansas School of Medicine. She completed her internship and residency at the University of Colorado Health Sciences Center and completed her fellowship in medical oncology at the University of Colorado Health Sciences Center.
Dr. Kelly is an internationally recognized lung cancer expert dedicated to providing enhanced cancer care through cutting-edge clinical trials. Dr. Kelly’s lung cancer research spans the spectrum of the disease from prevention to treatment. She has been at the forefront of clinical trials development evaluating drugs to treat lung cancer and novel compounds to prevent lung cancer. She is also involved in developing biomarkers for screening and early detection of lung cancer.
Dr. Kelly has authored or co-authored more than 190 publications, including original papers, reviews and book chapters. She frequently lectures on lung cancer topics, nationally and internationally. Dr. Kelly is a long-standing active member of ASCO, IASLC and SWOG and currently serves as the SWOG Lung Committee Chair.
Dr. Kelly is an internationally recognized lung cancer expert dedicated to providing enhanced cancer care through cutting-edge clinical trials. Dr. Kelly’s lung cancer research spans the spectrum of the disease from prevention to treatment. She has been at the forefront of clinical trials development evaluating drugs to treat lung cancer and novel compounds to prevent lung cancer. She is also involved in developing biomarkers for screening and early detection of lung cancer.
Dr. Kelly has authored or co-authored more than 190 publications, including original papers, reviews and book chapters. She frequently lectures on lung cancer topics, nationally and internationally. Dr. Kelly is a long-standing active member of ASCO, IASLC and SWOG and currently serves as the SWOG Lung Committee Chair.
Published in
Speakers
Dr. Kalemkerian is Professor of Medicine in the Division of Hematology/Oncology at University of Michigan. He currently serves as the Associate Division Chief for Faculty Development and Education, Associate Director of the Hematology/Oncology Fellowship Program, and Co-Director of the Thoracic Oncology Clinical Research Team. Clinically, he cares for people with lung cancer, thymoma, and mesothelioma, and his academic research interest is clinical and translational trials for thoracic cancers.
Dr. Kalemkerian received his undergraduate and medical degrees from Northwestern University. He then completed his residency in Internal Medicine at Northwestern Memorial Hospital and a fellowship in Medical Oncology at the Johns Hopkins Hospital. He was a physician-scientist at Wayne State University/Karmanos Cancer Institute from 1993-1999, and has been on faculty at the University of Michigan since 1999.
Dr. Kalemkerian’s honors include the receipt of the University of Michigan Outstanding Clinician Award and the ASCO Excellence in Teaching Award. Dr. Kalemkerian has given over 200 invited lectures, authored more than 175 research articles, reviews and book chapters, and edited two books on lung cancer.
Dr. Kalemkerian received his undergraduate and medical degrees from Northwestern University. He then completed his residency in Internal Medicine at Northwestern Memorial Hospital and a fellowship in Medical Oncology at the Johns Hopkins Hospital. He was a physician-scientist at Wayne State University/Karmanos Cancer Institute from 1993-1999, and has been on faculty at the University of Michigan since 1999.
Dr. Kalemkerian’s honors include the receipt of the University of Michigan Outstanding Clinician Award and the ASCO Excellence in Teaching Award. Dr. Kalemkerian has given over 200 invited lectures, authored more than 175 research articles, reviews and book chapters, and edited two books on lung cancer.
Published in
Speakers
Dr. Juergens received her medical degree from Georgetown University in Washington, D.C. She was an intern and resident in the Osler Internal Medicine Training Program at The Johns Hopkins Medical Institute. She completed a fellowship in medical oncology with a focus on upper aerodigestive malignancies as well at Johns Hopkins. Additionally, she completed her Ph.D. in Clinical Investigation at The Johns Hopkins Bloomberg School of Public Health. She was on the faculty at Johns Hopkins from 2007-2010 until she joined the faculty at McMaster University. Dr. Juergens’ clinical expertise is in lung and esophageal cancer. She chairs the Lung Disease Site Team at the Juravinski Cancer Centre in Hamilton, Ontario. She is the Head of the Department of Clinical Trials at the Juravinski Cancer Centre. She is a member of the Escarpment Cancer Research Institute. Her research focus has been in developmental therapeutics with a concentration on Phase I and II clinical trials. She is the chair of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee.
Published in
Speakers
Dr. Johnson joined Sarah Cannon in 2014 and serves as the program director of lung cancer research. Her responsibilities include leading the lung cancer clinical trial portfolio across the Sarah Cannon network. Dr. Johnson continues to work in early phase Drug Development as well as lead the Solid Tumor Immune Effector Cellular Therapy program at Sarah Cannon. She also currently serves as the Chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville, Tennessee.
Dr. Johnson received her undergraduate degree from the University of North Carolina, Chapel Hill where she was a Morehead scholar, and her medical degree from the University of Pennsylvania. She completed her residency in internal medicine at New York Presbyterian/Weill Cornell Medical Center and her fellowship in medical oncology and hematology at Memorial Sloan Kettering Cancer Center where she also served as chief fellow for one year. She spent four years as a faculty member at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Feinberg School of Medicine, where she was a founding member of the Northwestern Medical Developmental Therapeutics Institute.
She is board certified in internal medicine and medical oncology. Additionally, she is a partner of Tennessee Oncology, PLLC.
Published in
Speakers
